
NYSEHealthcareMedical - Diagnostics & Research
最新資料
US$45.31
−US$0.07 · -0.15%
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
前收盤價
US$45.31
−US$0.07 · -0.15%
盤後
US$45.31
US$0.00 · 0.00%
10月12日 下午4:00 ET
盤中時間採用ET。市場資料可能有所延遲。
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
日內區間
目前US$45.31
52週區間
目前US$45.31
盤中時間採用ET。市場資料可能有所延遲。
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
日內區間
目前US$45.31
52週區間
目前US$45.31
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 20.9億 USD | 19.78億 USD | 19.65億 USD | 21.42億 USD | 22.52億 USD |
| 銷貨成本 | 7.99億 USD | 10.11億 USD | 7.32億 USD | 7.57億 USD | 8.01億 USD |
| 毛利 | 12.91億 USD | 9.67億 USD | 12.34億 USD | 13.85億 USD | 14.51億 USD |
| 研究與開發 | 1.88億 USD | 1.93億 USD | 1.99億 USD | 1.9億 USD | 1.9億 USD |
| 銷售、一般及管理費用 | 5.84億 USD | 5.64億 USD | 5.79億 USD | 6.04億 USD | 5.84億 USD |
| 營業費用 | 7.71億 USD | 8.7億 USD | 8.24億 USD | 8.53億 USD | 8.21億 USD |
| 利息收入 | 6432萬 USD | 6801.6萬 USD | 7899.2萬 USD | 3275.7萬 USD | 955.5萬 USD |
| 利息支出 | 3325.6萬 USD | 4384.1萬 USD | 5341萬 USD | 5835.7萬 USD | 5447.7萬 USD |
| 折舊和攤銷 | 1.94億 USD | 2.03億 USD | 2.05億 USD | 2.08億 USD | 2.15億 USD |
| 營業利益 | 5.2億 USD | 9771.1萬 USD | 4.1億 USD | 5.31億 USD | 6.3億 USD |
| 淨利 | 4.25億 USD | 8359.1萬 USD | 3.41億 USD | 4.23億 USD | 5.13億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$43.01
下跌空間 5.08%| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月7日 | US$0.35Semi-Annual | 2026年7月7日 | 2026年7月14日 |
股息 | 2026年1月8日 | US$2.29Semi-Annual | 2026年1月8日 | — |
股息 | 2025年7月2日 | US$0.25Semi-Annual | 2025年7月2日 | 2025年7月10日 |
股息 | 2025年1月29日 | US$1.26Annual | 2025年1月29日 | 2025年1月29日 |
股息 | 2024年1月30日 | US$1.28Special | 2024年1月31日 | 2024年1月31日 |
股息 | 2017年1月25日 | US$1.04Irregular | 2017年1月26日 | — |
除息 2026年7月7日
US$0.35
Semi-Annual
2026年7月7日登記 · 支付日 2026年7月14日
除息 2026年1月8日
US$2.29
Semi-Annual
2026年1月8日登記
除息 2025年7月2日
US$0.25
Semi-Annual
2025年7月2日登記 · 支付日 2025年7月10日
除息 2025年1月29日
US$1.26
Annual
2025年1月29日登記 · 支付日 2025年1月29日
除息 2024年1月30日
US$1.28
Special
2024年1月31日登記 · 支付日 2024年1月31日
除息 2017年1月25日
US$1.04
Irregular
2017年1月26日登記
報告持有此股票曝險的交易所交易基金。
iShares Russell Mid-Cap ETFIWR3886.44萬0.07%567.65億 USD0.18%US$109.47-0.32%
iShares Russell 1000 Value ETFIWD2079.7萬0.03%829.47億 USD0.18%US$254.65+0.44%
First Trust Health Care AlphaDEX FundFXH1543.23萬1.39%11.13億 USD0.61%US$130.88+0.56%
iShares Russell Mid-Cap Value ETFIWS1419.48萬0.09%153.1億 USD0.23%US$165+0.07%
Invesco Biotechnology & Genome ETFPBE1217.15萬2.88%4.22億 USD0.59%US$96.405-0.51%
iShares Systematic Alternatives Active ETFIALT645.35萬0.08%76.38億 USD0.99%US$30.00-0.30%
iShares Russell 1000 ETFIWB642.83萬0.01%496.24億 USD0.15%US$424.93-0.09%
iShares U.S. Healthcare ETFIYH594.99萬0.15%41.76億 USD0.37%US$72.55+0.57%
iShares Russell Mid-Cap ETFIWR
iShares Russell 1000 Value ETFIWD
First Trust Health Care AlphaDEX FundFXH
iShares Russell Mid-Cap Value ETFIWS
Invesco Biotechnology & Genome ETFPBE
iShares Systematic Alternatives Active ETFIALT
iShares Russell 1000 ETFIWB
iShares U.S. Healthcare ETFIYHAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。